[HTML][HTML] Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation
S Chandran, F Vincenti - American Journal of Transplantation, 2024 - Elsevier
New therapies directed against plasma cells such as anti-CD38 antibodies and the
bispecific anti–B cell maturation antigen antibodies, represent not only an important …
bispecific anti–B cell maturation antigen antibodies, represent not only an important …
Searching for the minimum required dose of daratumumab to induce effective plasma cell depletion in antibody-mediated rejection of the kidney graft: a case report
J Ollé, AB Larque, CF de Larrea, F Diekmann… - Journal of …, 2025 - Springer
There is no established treatment for late or chronic antibody-mediated rejection of a kidney
graft. Rituximab-based treatment is not effective, since long-lived high-affinity plasma cells …
graft. Rituximab-based treatment is not effective, since long-lived high-affinity plasma cells …
[引用][C] Life beyond Antibodies: Quality of Life after Desensitization in Kidney Transplantation
P Zoehinga, T Jouve, E Chevalier… - Clinical Kidney …, 2025 - academic.oup.com
To the Editor, about 35% of kidney transplant candidates have pre-existing anti-Human
Leukocyte Antigen (HLA) and about 11% are highly sensitized, ie have a cPRA> 80% 1. For …
Leukocyte Antigen (HLA) and about 11% are highly sensitized, ie have a cPRA> 80% 1. For …